Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
- GATHER2 Enrollment
- GATHER2 Enrollment Nears Completion; Timeline Accelerated to Late July of this Year -
- GATHER2 Retention Exceeding Expectations; with Injection Fidelity Rate Target for GATHER2 Greater